JP2014534245A5 - - Google Patents

Download PDF

Info

Publication number
JP2014534245A5
JP2014534245A5 JP2014542594A JP2014542594A JP2014534245A5 JP 2014534245 A5 JP2014534245 A5 JP 2014534245A5 JP 2014542594 A JP2014542594 A JP 2014542594A JP 2014542594 A JP2014542594 A JP 2014542594A JP 2014534245 A5 JP2014534245 A5 JP 2014534245A5
Authority
JP
Japan
Prior art keywords
capsid
viral
viral vector
aav
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014542594A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014534245A (ja
JP6348064B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/066380 external-priority patent/WO2013078400A1/en
Publication of JP2014534245A publication Critical patent/JP2014534245A/ja
Publication of JP2014534245A5 publication Critical patent/JP2014534245A5/ja
Application granted granted Critical
Publication of JP6348064B2 publication Critical patent/JP6348064B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014542594A 2011-11-22 2012-11-21 効率の高いトランスジーン送達のためのウイルスベクター Active JP6348064B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161562795P 2011-11-22 2011-11-22
US61/562,795 2011-11-22
US201261639025P 2012-04-26 2012-04-26
US61/639,025 2012-04-26
US201261682019P 2012-08-10 2012-08-10
US61/682,019 2012-08-10
PCT/US2012/066380 WO2013078400A1 (en) 2011-11-22 2012-11-21 Virus vectors for highly efficient transgene delivery

Publications (3)

Publication Number Publication Date
JP2014534245A JP2014534245A (ja) 2014-12-18
JP2014534245A5 true JP2014534245A5 (OSRAM) 2016-01-14
JP6348064B2 JP6348064B2 (ja) 2018-06-27

Family

ID=48470322

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014542594A Active JP6348064B2 (ja) 2011-11-22 2012-11-21 効率の高いトランスジーン送達のためのウイルスベクター

Country Status (7)

Country Link
US (1) US10640785B2 (OSRAM)
EP (2) EP2782596A4 (OSRAM)
JP (1) JP6348064B2 (OSRAM)
AU (1) AU2012340567B2 (OSRAM)
CA (1) CA2856137A1 (OSRAM)
HK (1) HK1202434A1 (OSRAM)
WO (1) WO2013078400A1 (OSRAM)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100183558A1 (en) 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
KR20140041505A (ko) 2011-04-29 2014-04-04 셀렉타 바이오사이언시즈, 인크. 조절 b 세포 유도를 위한 관용원성 합성 나노운반체
WO2014043480A1 (en) 2012-09-13 2014-03-20 Crystal Ronald G Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
EP3434776A1 (en) 2012-12-12 2019-01-30 The Broad Institute, Inc. Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
IL239317B (en) 2012-12-12 2022-07-01 Broad Inst Inc Providing, engineering and optimizing systems, methods and compositions for sequence manipulation and therapeutic applications
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
BR112015027291A8 (pt) 2013-05-03 2019-12-24 Selecta Biosciences Inc uso de um imunossupressor que têm uma vida eficaz farmacodinâmica especificada e composição compreendendo o referido imunossupressor
JP6738729B2 (ja) * 2013-06-17 2020-08-12 ザ・ブロード・インスティテュート・インコーポレイテッド 分裂終了細胞の疾患および障害をターゲティングおよびモデリングするための系、方法および組成物の送達、エンジニアリングおよび最適化
CN105793425B (zh) 2013-06-17 2021-10-26 布罗德研究所有限公司 使用病毒组分靶向障碍和疾病的crispr-cas系统和组合物的递送、用途和治疗应用
MX2015017312A (es) 2013-06-17 2017-04-10 Broad Inst Inc Suministro y uso de composiciones, vectores y sistemas crispr-cas para la modificación dirigida y terapia hepáticas.
JP6665088B2 (ja) 2013-06-17 2020-03-13 ザ・ブロード・インスティテュート・インコーポレイテッド 配列操作のための最適化されたCRISPR−Cas二重ニッカーゼ系、方法および組成物
WO2014204724A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
EP3725885A1 (en) 2013-06-17 2020-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
AU2014287005C1 (en) * 2013-07-12 2021-06-03 The Children's Hospital Of Philadelphia AAV vector and assay for anti-AAV (adeno-associated virus) neutralizing antibodies
PT3024498T (pt) * 2013-07-22 2020-03-06 Childrens Hospital Philadelphia Variante aav e composições, métodos e usos para transferência genética em células, órgãos e tecidos
WO2015035190A1 (en) * 2013-09-05 2015-03-12 Cornell University Gene therapy for alzheimer's and other neurodegenerative diseases and conditions
CN111206032B (zh) 2013-12-12 2024-07-19 布罗德研究所有限公司 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
WO2015089473A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
WO2015089486A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
BR112016013547A2 (pt) 2013-12-12 2017-10-03 Broad Inst Inc Composições e métodos de uso de sistemas crispr-cas em distúrbios de repetições de nucleotídeos
RU2016128077A (ru) 2013-12-12 2018-12-06 Те Брод Инститьют Инк. Доставка, применение и применения в терапии систем и композиций crispr-cas для лечения обусловленных hbv и вирусных заболеваний и нарушений
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
WO2015196179A1 (en) 2014-06-20 2015-12-23 University Of Florida Research Foundation, Inc. Methods of packaging multiple adeno-associated virus vectors
WO2016037164A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
US10370432B2 (en) * 2014-10-03 2019-08-06 University Of Massachusetts Heterologous targeting peptide grafted AAVS
WO2016055437A1 (en) * 2014-10-06 2016-04-14 Arthrogen B.V. Aav-based gene therapy
RU2020140209A (ru) * 2014-10-21 2021-01-25 Юниверсити Оф Массачусетс Варианты рекомбинантных aav и их применения
CN107106689A (zh) 2014-11-05 2017-08-29 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
CN112410338A (zh) 2014-11-14 2021-02-26 沃雅戈治疗公司 调节性多核苷酸
IL292999A (en) 2014-11-14 2022-07-01 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
EP3230451B1 (en) 2014-12-12 2021-04-07 The Broad Institute, Inc. Protected guide rnas (pgrnas)
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
CA2970370A1 (en) 2014-12-24 2016-06-30 Massachusetts Institute Of Technology Crispr having or associated with destabilization domains
US10081659B2 (en) 2015-04-06 2018-09-25 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Adeno-associated vectors for enhanced transduction and reduced immunogenicity
US10293059B2 (en) 2015-04-09 2019-05-21 Cornell University Gene therapy to prevent reactions to allergens
KR20180014051A (ko) * 2015-05-28 2018-02-07 코넬 유니버시티 혈관 부종 치료제로서의 아데노-관련 바이러스 매개 c1e1의 전달
WO2016205759A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
IL293323B2 (en) 2015-06-18 2024-01-01 Massachusetts Inst Technology Crispr enzyme mutations reducing off-target effects
PT3313991T (pt) 2015-06-23 2024-09-27 Childrens Hospital Philadelphia Fator ix modificado e composições, métodos e utilizações para transferência de genes para células, órgãos e tecidos
WO2017007994A1 (en) 2015-07-08 2017-01-12 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
WO2017096162A1 (en) 2015-12-02 2017-06-08 Voyager Therapeutics, Inc. Assays for the detection of aav neutralizing antibodies
CN111569090A (zh) 2016-01-15 2020-08-25 美国基因技术国际有限公司 用于活化γ-δ T细胞的方法和组合物
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
JP7153332B2 (ja) 2016-02-08 2022-10-14 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Hivワクチン接種および免疫療法
ES2911448T3 (es) 2016-03-09 2022-05-19 American Gene Tech Int Inc Vectores combinados y métodos para el tratamiento del cáncer
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
JP2019519501A (ja) * 2016-05-12 2019-07-11 ブライアン ピー. ハンリーBrian P. HANLEY ヒトおよび動物における体細胞の大部分へのcrisprおよび他の遺伝子治療薬の安全な送達
KR20220108216A (ko) 2016-05-18 2022-08-02 보이저 테라퓨틱스, 인크. 헌팅톤 질환을 치료하기 위한 조성물 및 방법
SG11201809699XA (en) 2016-05-18 2018-12-28 Voyager Therapeutics Inc Modulatory polynucleotides
US11976292B2 (en) * 2016-06-08 2024-05-07 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
EP3481418A4 (en) 2016-07-08 2020-03-11 American Gene Technologies International Inc. PRE-IMMUNIZATION AND IMMUNOTHERAPY OF HIV
US11583562B2 (en) 2016-07-21 2023-02-21 American Gene Technologies International Inc. Viral vectors for treating Parkinson's disease
CN110650673B (zh) 2016-08-30 2024-04-09 加利福尼亚大学董事会 用于生物医学靶向和递送的方法以及用于实践该方法的装置和系统
CA3040483A1 (en) 2016-10-13 2018-04-19 University Of Massachusetts Aav capsid designs
CA3040179A1 (en) 2016-10-19 2018-04-26 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
US11116852B2 (en) 2016-11-09 2021-09-14 Precigen, Inc. Frataxin expression constructs
CA3052829A1 (en) * 2017-02-15 2018-08-23 The University Of North Carolina At Chapel Hill Methods and compositions for gene transfer across the vasculature
KR102753928B1 (ko) 2017-03-11 2025-01-14 셀렉타 바이오사이언시즈, 인크. 항염증제, 및 면역억제제를 포함하는 합성 나노담체를 사용한 조합 치료와 관련된 방법 및 조성물
JP2020512815A (ja) 2017-04-03 2020-04-30 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド フェニルケトン尿症を処置するための組成物および方法
WO2018191450A2 (en) 2017-04-14 2018-10-18 National Taiwan University Hospital Gene therapy for aadc deficiency
SG11201909870SA (en) 2017-05-05 2019-11-28 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. ハンチントン病治療組成物および方法
KR102386890B1 (ko) 2017-05-22 2022-04-15 다케다 야쿠힌 고교 가부시키가이샤 B형 혈우병 유전자 요법을 위한 증가된 발현을 가지는 재조합 fix 변이체를 암호화하는 바이러스 벡터
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
WO2018232359A1 (en) 2017-06-16 2018-12-20 American Gene Technologies International Inc. Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells
JP7229989B2 (ja) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド 軌道アレイガイドシステム
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
EP4454654A3 (en) 2017-10-16 2025-02-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
US20210371877A1 (en) * 2017-12-18 2021-12-02 Spark Therapeutics, Inc. Adeno-associated virus (aav) vector lipid nanoparticle compositions and methods of use
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
AU2019215152A1 (en) 2018-02-01 2020-08-20 Homology Medicines, Inc. Adeno-associated virus compositions for restoring PAH gene function and methods of use thereof
JP7244547B2 (ja) 2018-02-19 2023-03-22 ホモロジー・メディシンズ・インコーポレイテッド F8遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法
CN112292150A (zh) * 2018-03-13 2021-01-29 加利福尼亚大学董事会 用于口服递送胰岛素的病毒样纳米衣壳
WO2019195444A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
JP7406677B2 (ja) 2018-04-03 2023-12-28 ギンコ バイオワークス インコーポレイテッド 抗体を回避するウイルスベクター
WO2019195423A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Virus vectors for targeting ophthalmic tissues
WO2019200016A1 (en) 2018-04-10 2019-10-17 President And Fellows Of Harvard College Aav vectors encoding clarin-1 or gjb2 and uses thereof
EP3794126A1 (en) 2018-05-15 2021-03-24 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
PL3802570T3 (pl) * 2018-06-06 2024-03-18 The Regents Of The University Of California Ulepszone wirusopodobne nanocząstki do podawania doustnego
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
CN113383010B (zh) 2018-09-28 2025-09-09 沃雅戈治疗公司 具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法
BR112021009452A2 (pt) * 2018-11-16 2021-08-17 Spark Therapeutics, Inc. ensaio in vitro para detectar intensificadores e inibidores de transdução de vetor de vírus adeno-associados (aav) e/ou detectar ou quantificar anticorpos de ligação a anti-aav
AR118465A1 (es) 2019-03-21 2021-10-06 Stridebio Inc Vectores de virus adenoasociados recombinantes
WO2020208379A1 (en) 2019-04-12 2020-10-15 Freeline Therapeutics Limited Plasmid system
ES2928689T3 (es) 2019-04-12 2022-11-22 Freeline Therapeutics Ltd Sistema de plásmidos
EP3980784A1 (en) 2019-06-04 2022-04-13 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
US20200405824A1 (en) * 2019-06-26 2020-12-31 University Of Washington Use of ribonucleotide reductase alone or in combination with micro-dystrophin to treat duchenne muscular dystrophy striated muscle disease
MX2022001425A (es) * 2019-08-01 2022-05-02 Univ North Carolina Chapel Hill Composiciones y metodos para la union de anticuerpos y la inhibicion de anticuerpos neutralizantes.
US11155835B2 (en) * 2019-08-19 2021-10-26 The Catholic University Of America Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells
KR20220083708A (ko) 2019-10-17 2022-06-20 스트라이드바이오 인코포레이티드 Aav 전달 카세트
AU2020367532A1 (en) 2019-10-17 2022-05-12 Ginkgo Bioworks, Inc. Adeno-associated viral vectors for treatment of Niemann-Pick disease type C
EP4055151A1 (en) 2019-11-08 2022-09-14 Coave Therapeutics Modified adeno-associated virus vectors and delivery thereof into the central nervous system
IL293658A (en) * 2019-12-10 2022-08-01 Homology Medicines Inc Adeno-associated virus preparations and a method of using them
TW202140791A (zh) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
US20230190956A1 (en) * 2020-04-24 2023-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing induction of immune responses to the transduced cells expressing a transgene product after ocular gene therapy
TW202208632A (zh) 2020-05-27 2022-03-01 美商同源醫藥公司 用於恢復pah基因功能的腺相關病毒組成物及其使用方法
MX2023002016A (es) 2020-08-19 2023-06-26 Sarepta Therapeutics Inc Vectores de virus adenoasociados para el tratamiento del sindrome de rett.
US12129287B2 (en) 2020-09-14 2024-10-29 President And Fellows Of Harvard College Recombinant adeno associated virus encoding clarin-1 and uses thereof
GB202016254D0 (en) 2020-10-13 2020-11-25 Freeline Therapeutics Ltd Plasmid system
CN116802279A (zh) 2020-11-06 2023-09-22 科亚韦治疗公司 内酰胺修饰的腺相关病毒载体
EP4727963A2 (en) * 2023-06-14 2026-04-22 Fractyl Health, Inc. Gene therapies for metabolic disorders
EP4628576A1 (en) 2024-04-07 2025-10-08 Ascend Advanced Therapies GmbH Microrna molecules for use in methods for improving recombinant aav production
WO2025238067A1 (en) 2024-05-15 2025-11-20 Ascend Advanced Therapies Gmbh Novel vector system for aav production

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1202962A (en) 1982-10-19 1986-04-08 David P. Clifford Substituted n-phenyl-n'-benzoyl ureas and their use as insecticides and acaricides
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
JP2001500015A (ja) 1996-09-06 2001-01-09 トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア T7ポリメラーゼを利用する組換えアデノ随伴ウイルスの誘導可能な製造方法
AU773834B2 (en) 1998-12-03 2004-06-10 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
US20080220015A1 (en) 2001-08-03 2008-09-11 Nokad, S.A. Method of modulating neutralizing antibodies formation in mammals, and uses thereof in gene therapy, animal trangenesis and in functional inactivation of endogenous proteins
CA2479759A1 (en) 2002-03-22 2003-10-09 Board Of Regents, The University Of Texas System Protamine-adenoviral vector complexes and methods of use
US8802080B2 (en) 2002-05-01 2014-08-12 University Of Florida Research Foundation, Inc. Raav expression systems for genetic modification of specific capsid proteins
ATE506445T1 (de) 2003-02-17 2011-05-15 Fuso Pharmaceutical Ind Neuartiger virusvektor
BRPI0511764B8 (pt) 2004-06-01 2021-05-25 Avigen Inc método de prevenção de agregação de vírions de vírus adeno-associado recombinante (raav) em uma preparação purificada de virions raav
EP1799826B1 (en) * 2004-09-29 2009-08-12 Children's Memorial Hospital siRNA-MEDIATED GENE SILENCING OF ALPHA SYNUCLEIN
CN101495624A (zh) * 2006-04-28 2009-07-29 宾夕法尼亚州立大学托管会 衣壳免疫原性降低的经修饰aav载体及其用途
KR102057540B1 (ko) * 2012-02-17 2019-12-19 더 칠드런스 호스피탈 오브 필라델피아 세포, 기관 및 조직으로의 유전자 전이를 위한 aav 벡터 조성물 및 방법

Similar Documents

Publication Publication Date Title
Zhao et al. Viral vector‐based gene therapies in the clinic
JP6373763B2 (ja) Aavベクター成分、及び、細胞、臓器並びに組織への遺伝子導入のための方法
JP2022065003A (ja) パルボウイルスベクターの高められた送達のための改変キャプシドタンパク質
US10640785B2 (en) Virus vectors for highly efficient transgene delivery
Cao et al. Adenoviral vectors for gene replacement therapy
Gorecki Prospects and problems of gene therapy: an update
KR20160033217A (ko) 변종 aav 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도
KR20160026841A (ko) 스터퍼/필러 폴리누클레오티드 서열을 포함하는 벡터 및 사용 방법
KR20180091863A (ko) 임상적 사용에 적합한 무혈청 현탁 세포 배양 시스템에서 재조합 아데노-관련 바이러스(aav) 벡터를 생성하기 위한 확장가능한 방법
WO2015124546A1 (en) Aav vectors for the treatment of ischemic and non-ischemic heart disease
IL298772A (en) Coding-optimized nucleic acid encoding the SMN1 protein and its use
EP4509606A1 (en) Nucleic acid construct for treating hereditary coagulation factor deficiency and use thereof
Geiger et al. Vectors for pulmonary gene therapy
JP4219335B2 (ja) インターフェロンβのような分泌タンパク質をコードする遺伝子を使用する治療のための方法および組成物
Ziady et al. Current prospects for gene therapy of cystic fibrosis
US20170065685A1 (en) Serca2 therapeutic compositions and methods of use
US6165754A (en) Method of expressing an exogenous nucleic acid
Hausl et al. Development of adenovirus hybrid vectors for Sleeping Beauty transposition in large mammals
Usman et al. Recombinant Adeno-Associated Viruses as a Gene Delivery Vehicle for the Use in Molecular Medicine
JP2005502585A (ja) 治療的核酸の送達を増強するための方法
WO2024233783A1 (en) Expression cassette coding for vascular endothelial growth factor
CN113573741B (zh) 修饰腺病毒和含有其的医药
WO2009125902A1 (en) Adeno associated virus serotype five vector for targeted gene delivery
Rubanyi Gene therapy—basic principles and the road from bench to bedside
Fradkin et al. Gene-based therapeutics